Hemab Reports Positive HMB-002 Data
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 Hemab Therapeutics announced encouraging new clinical findings from its HMB-002 program...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 Hemab Therapeutics announced encouraging new clinical findings from its HMB-002 program...
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
SOUTH SAN FRANCISCO, Calif., June 26, 2026 Star Therapeutics announced it will present complete safety and efficacy data from...
WILMINGTON, Delaware, USA – June 8, 2026 Incyte Corporation has announced a definitive agreement to acquire Vega Therapeutics, a...
